The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preference of end-of-life discussion at diagnosis in patients with advanced/recurrent cancer.
 
Aiko Maejima
No Relationships to Disclose
 
Saran Yoshida
No Relationships to Disclose
 
Shun Kudo
No Relationships to Disclose
 
Hiroko Bando
No Relationships to Disclose
 
Kenjiro Aogi
No Relationships to Disclose
 
Eriko Tokunaga
No Relationships to Disclose
 
Masayuki Furukawa
No Relationships to Disclose
 
Hiroyuki Otani
No Relationships to Disclose
 
Ken Shimizu
No Relationships to Disclose
 
Yasunari Sakamoto
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Fujifilm; Lilly; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Nippon Boehringer Ingelheim; Tactical Therapeutics; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline K.K.; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shizuoka Industry; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
 
Tatsuya Morita
No Relationships to Disclose
 
Chikako Shimizu
Research Funding - Chugai Pharma; Lilly; Pfizer